News | June 06, 2022
Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The Da Vinci Robotic-Assisted Surgery system, and Advanced Robotic Surgery Centre was inaugurated early this year
Investment with representation on the Board of Directors and technical know-how
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Subscribe To Our Newsletter & Stay Updated
